Description

Diabeton MR Tablets 60 mg, #30

Composition

Each modified-release (MR) tablet contains 60 mg of the active substance Gliclazide. Inactive ingredients include hypromellose, magnesium stearate, lactose monohydrate, and other excipients that support modified-release pharmacokinetics.

Description

Diabeton MR is an oral antidiabetic drug belonging to the class of sulfonylureas. It is used in the treatment of type 2 diabetes mellitus (non-insulin-dependent diabetes) to improve glycemic control. The modified-release formulation ensures gradual absorption of Gliclazide, providing sustained plasma concentrations and reducing the risk of hypoglycemia.

Pharmacological Action

Gliclazide lowers blood glucose by stimulating insulin secretion from pancreatic β-cells. This action is glucose-dependent, meaning insulin release is increased only when glucose levels are elevated, which helps reduce the risk of hypoglycemia compared to older sulfonylureas. Additionally, Gliclazide improves endothelial function and exhibits antioxidant properties, potentially contributing to cardiovascular risk reduction.

Indications

Diabeton MR is indicated for:

• Adults with type 2 diabetes mellitus inadequately controlled by diet, exercise, and weight loss alone
• Monotherapy or combination therapy with other antidiabetic agents (e.g., metformin, DPP-4 inhibitors)

Dosage and Administration

The typical starting dose is 30–60 mg (½ to 1 tablet) once daily with breakfast. Dosage adjustments should be made in 30 mg increments at 2–4 week intervals, based on blood glucose monitoring. The maximum recommended daily dose is 120 mg. Tablets should be swallowed whole, not crushed or chewed.

Contraindications

• Type 1 diabetes mellitus
• Diabetic ketoacidosis
• Severe renal or hepatic impairment
• Known hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides
• Pregnancy or breastfeeding

Precautions

Patients must be educated to recognize hypoglycemia symptoms (e.g., sweating, hunger, tremor, visual disturbances) and manage them promptly. Close monitoring is required in elderly patients and those with irregular eating habits or strenuous physical activity. Diabeton MR should be used cautiously in patients at risk of cardiovascular events.

Side Effects

• **Common:** Hypoglycemia, headache, nausea, dyspepsia, diarrhea
• **Uncommon:** Skin rash, pruritus, dizziness
• **Rare but serious:** Liver dysfunction, hematologic disorders (e.g., leukopenia, thrombocytopenia)

If any adverse effect occurs, consult a healthcare provider promptly.

Drug Interactions

Caution is advised when Diabeton MR is co-administered with:

• **Potentiating agents:** Azole antifungals, beta-blockers, MAO inhibitors, NSAIDs, sulfonamides
• **Inhibiting agents:** Corticosteroids, diuretics, oral contraceptives, thyroid hormones

Always inform your healthcare provider of all current medications and supplements.

Overdose

Symptoms of overdose primarily involve hypoglycemia. Mild hypoglycemia can be treated with oral glucose. Severe hypoglycemia may require intravenous glucose or hospitalization.

Storage

Store below 25°C in a dry place, protected from light and moisture. Keep out of reach of children.

Scientific References

• Gliclazide MR in the treatment of type 2 diabetes: efficacy and cardiovascular safety (PubMed)
• Gliclazide MR: Clinical pharmacology and evidence-based use (NCBI)

Conclusion

Diabeton MR is a reliable and effective option for managing type 2 diabetes mellitus. Its modified-release formula offers steady blood glucose control with a lower risk of hypoglycemia. When combined with lifestyle modifications, Diabeton MR supports long-term glycemic targets and reduces diabetes-related complications.